To confirm the SV2A-specific uptake of 18F-SynVesT-1 in the NCI-H660 tumor, we performed the blocking study with a co-injection of 19F-SynVesT-1 (0.1 mg, 0.033 μmol). This evidence concerns the gene SV2A and neoplasm.